Helix TCS Stock (OTCMKTS:HLIX) is turning out to be an interesting pick after a steep pullback in 2019. The stock appears to be trading at a big discount going by the solid fundamentals that support a bounce back from current lows. If you are looking for a company seeing plenty of opportunities on the horizon then Helix TCS stock fits the bill.
Helix TCS Stock Catalysts and Price Analysis
The company is currently ranked at number 32 on the Deloitte Technology 500 fastest growing companies. The impressive rating stems from the company reporting impressive financial results depicted by an 80% increase in revenue and a 39% increase in cash flow from operations.
Likewise, the company has moved to strengthen its prospects in the hemp business by launching the nation’s first hemp tracking system. Similarly, the company has inked a strategic partnership with Alt Thirty Six for the launch of digital payments targeting thousands of dispensaries across the U.S
Reports that Helix TCS BioTrack traceability stem processed over $11 million transactions in the first week of recreational sales attest to what could turn out to be a break out year for the company and its technology.
It thus does not come as a surprise that the company’s stock has started to pick up some steam after a roller coaster 2019. A 10% plus rally since the start of the year affirms renewed investor interest in response to the wave of positive developments in recent weeks.
After a recent spike higher, the stock faces immediate resistance at the $0.63 level as part of the bounce-back play. A rally followed by a close above the $0.63 level should open the door for the stock to make a run for the $0.77 mark, the next substantial resistance level.
The stock rising and finding support above the $0.77 mark should bring to an end the sell-off wave that had plunged the stock to all-time lows. Conversely, failure to take out the $0.63 level could leave the stock susceptible to further drops in continuation of the long-term bear trend.
About Helix TCS stock
Helix TCS casts itself as a leading provider of crucial infrastructure and technology that helps licensed cannabis businesses stay competitive in the multi-billion-dollar industry. The company boasts of an array of proprietary technology and security services used in enhancing supply management as well as asset protection. The company’s solutions are currently in use in over 2,000 customer locations in 38 states across the U.S and six countries.
BioTrack System Boost
Helix TCS sentiments and prospects have edged higher in the market on the confirmation that its proprietary BioTrack traceability system used in adult-use marijuana sales has processed over $11 million worth of sales.
On its first day of use in the state of Illinois, the system processed over $3.2 million in transactions with the numbers expected to continue increasing as the state continues to issue more licenses. The BioTrack system is designed to provide licensed cannabis operators a platform for managing business and maintaining compliance.
Digital Payment Opportunity
Likewise, Helix TCS has inked a partnership with Alt Thirty Six to enable digital payment payments in-store as well as online and on delivery services. The partnership will allow thousands of cannabis dispensaries across the U.S to accept digital payments consequently alleviate the risk of dealing with cash and credit cards.
“The primary mission of Helix Technologies is to be the leading provider of critical infrastructure services in the cannabis industry. By partnering with Alt Thirty-Six, we are able to provide our dispensary partners with yet another tool to help them run an efficient and compliant business,” said Moe Afaneh, COO at Helix BioTrack.
The unveiling of the BioTrack system in Illinois comes hot on the heels of the company launching an integrated hemp-tracking module in Delaware. The system allows operators to import hemp derivatives into medical cannabis products consequently ensuring patients get exactly what they asked for.
The tide is slowly turning in favor of Helix TCS stock after coming under immense pressure in 2019. Improved operational efficiency with the launch of the BioTrack system is one of the key developments that continues to shape the company’s prospects.
Strategic acquisitions, as well as an increased focus on the customer and targeted internal improvements, should continue to drive growth and consequently shareholder value going forward. Improving fundamentals and positive developments provide clear evidence of positive trend materializing. In our view, Helix TCS stock looks set to continue bottoming out from current lows
We will be updating our subscribers as soon as we know more. For the latest updates on Helix TCS stock, sign up below!
Disclosure: We have no position in Helix TCS stock and have not been compensated for this article.
Forget APHA and ACB, Buy GTBIF and TCNNF
There are a lot of misconceptions going on when it comes to US legalization. Many investors are buying Aphria (APHA) and Aurora Cannabis (ACB) hoping to bank on what’s happening in the US. However, they are Canadian Licensed Producers and have no business in the US. Investors are buying them because they trade on the major exchanges, but that is the wrong move. The correct move is to buy the US multi-state operators like Green Thumb Industries (GTBIF) and Trulieve Cannabis (TCNNF).
On Election Day voters in New Jersey, Arizona, Montana and South Dakota voted to legalize recreational marijuana. South Dakota and Mississippi voters also approved measures to legalize medical marijuana.
There’s also the prospect of a more pot-friendly White House with President-elect Joe Biden. Vice Presidential Candidate Kamala Harris said at the debate a Biden administration would decriminalize marijuana at a federal level and expunge criminal records of people with marijuana-related offenses.
Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves.
Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Dr. Solomon’s, incredibles, Rythm and The Feel Collection.
The company also owns and operates rapidly growing national retail cannabis stores called Rise™ and Essence. Headquartered in Chicago, Illinois, Green Thumb has 13 manufacturing facilities, licenses for 96…
Decision Diagnostics Corp (OTCMKTS:DECN) Explodes On COVID-19 Test Kit Opportunity
Decision Diagnostics Corp (OTCMKTS:DECN) is exploding higher after unveiling a new methodology for the screening of coronavirus. GenViroTM COVID-19 screening kit is the latest catalysts fuelling the stock’s price action activity in the market. Similarly, the stock has rallied by more than 300% as investors take note of the huge opportunity up for grabs as the coronavirus pandemic continues to cause havoc.
OTCMKTS:DECN Price Analysis
The ever-growing demand for coronavirus test kit presents a unique opportunity for the company to generate significant value. In return, investors have continued to push the stock higher even as the broader equity market continues to plunge into the bear territory.
OTCMKTS:DECN is currently trading in a steep uptrend after succumbing to bearish pressure in 2019. Given the strength of the upward momentum, the stock is closing in on its one-year highs as the break out shows no signs of slowing down. A rally followed by a close above the $0.08 mark should open the door for bulls to push the stock to two-year highs.
Similarly, the $0.05 mark is the immediate support level above which the stock remains a bull play. Conversely, a breach of the support level would leave Decision Diagnostics susceptible to further drops, probably back to the $0.03 level. However, given the developments on the global scene, the stock looks set to continue powering high on pullbacks.
Decision Diagnostics bills itself…
Is CytoDyn Inc. (OTCMKTS:CYDY) A Buy?
CytoDyn Inc (OTCMKTS:CYDY) has been making big moves lately, which have propelled the stock from December low of $0.270 to new highs. Notably, CytoDyn’s surge has come on significant volume as well, a clear sign of strong investor interest in the stock.
The excitement in CytoDyn stock that we are witnessing right now comes as the company has taken a leading role in the fight against the deadly Wuhan coronavirus. Moreover, investors have started pouring on CytoDyn stock as the company advances the development of its lead drug candidate as a treatment for about two dozen different cancer types.
Before we delve into the details, here is a brief profile of CytoDyn for those investors who may have just come across this company for the very first time.
CytoDyn operates in the healthcare sector as a biotechnology company. It is engaged in developing innovative treatments for a broad range of medical indications. Its lead product candidate is leronlimab (PRO 140). Clinical trials of leronlimab are ongoing for conditions such as HIV and multiple cancers with impressive results already attained. But CytoDyn is expanding its target conditions with leronlimab in the wake of the outbreak of the Wuhan coronavirus.
Here are some of the recent developments at CytoDyn that have excited renewed investor interest in its stock.
CytoDyn’s leronlimab under consideration as Wuhan potential coronavirus treatment
CytoDyn’s lead drug candidate leronlimab (PRO 140)…